Comment on FR Doc # 2012-04982

The placement of JWH-018, JWH-200, JWH-073, CP-47,497 and cannabicyclohexanol as a Schedule I drugs under the CSA is a good policy choice for public safety, and to prevent abuse. However, I find it useful to further identify whether only these specific combinations or blends are Schedule I drugs under the CSA, or if each separate component alone is also a Schedule I drug under the CSA. I believe to propose permanently placing these five synthetic cannabinoids as Schedule I drugs under the CSA will only create more work and a need to edit the rule in the future. As technology and science continue to improve, there is always possibility of discovering some medical use for these synthetic cannabinoids and/or their salts and isomers. To classify any drug as a Schedule I drug under the CSA permanently would only create more work for the DEA in the future when new technology may provide the discovery of medical uses. A good alternative may be to classify these five synthetic cannabinoids and their salts and isomers as Schedule I drugs under the CSA subject to discovery of any and all medical uses by further and future medical and scientific studies and research. Thank You